Stifel analyst Daniel Arias maintains $Thermo Fisher Scientific (TMO.US)$ with a buy rating, and adjusts the target price from $680 to $665.
According to TipRanks data, the analyst has a success rate of 39.3% and a total average return of -9.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Thermo Fisher Scientific (TMO.US)$'s main analysts recently are as follows:
The company delivered results that matched market anticipations amid heightened expectations. There is recognition of the company's strong execution within a challenging tools demand climate, coupled with a current lack of clarity regarding the timing of demand resurgence.
The company's third-quarter earnings discussion was seen as more optimistic than actual results, and there remains a positive outlook on the stock. This is due to sustained momentum in the Life Sciences Solutions segment and stable sales within the Laboratory Products and Biopharma Services segment, which appears to be resilient to the biotech downturn.
Thermo Fisher is showing a consistent improvement in core growth with quarter-over-quarter increments, and projections suggest a modest rise to approximately +2.5% in the fourth quarter. Expectations for a 5% core growth rate in 2025 appear to be reasonable and justifiable. The company's defensive profile and the potential of its balance sheet continue to be favorable aspects.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
斯迪富分析師Daniel Arias維持$賽默飛世爾 (TMO.US)$買入評級，並將目標價從680美元下調至665美元。
根據TipRanks數據顯示，該分析師近一年總勝率為39.3%，總平均回報率為-9.8%。
此外，綜合報道，$賽默飛世爾 (TMO.US)$近期主要分析師觀點如下：
該公司發佈的結果符合市場預期，儘管市場對其抱有較高期望。在需求環境嚴峻的情況下，公司展現出強大的執行力，同時目前對需求復甦時機缺乏明確認識。
該公司第三季度盈利討論被認爲比實際結果更樂觀，且對股票仍然持有正面展望。這要歸功於生命科學解決方案部門的持續勢頭，以及實驗室產品和生物製藥服務部門的穩定銷售，似乎能夠抵禦生物技術行業低迷。
賽默飛世爾正在持續改善核心增長，季度間呈現增長，預測顯示第四季度將略有增長約+2.5%。對於2025年核心增長率達到5%的預期似乎是合理且可證明的。該公司的防禦性質和資產負債表潛力繼續保持有利。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
